Posted on by Cynthia Johnson

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT#: & LinkNCT04928846
NCT QR Code
Available as of:July 15, 2024
Contract:Caris
Indication Category:Lung
Study Sponsor:AbbVie
Protocol #:M18-868
Title:A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Highlight Details:**REFERRAL ONLY** A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV- 399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung
Cancer
Biomarkers:c-MET
Indication:NSCLC 
Phase:3
Treatment Line:
Study Drug/Test Compound:Telisotuzumab Vedotin (ABBV-399)
Notes
Recruitment Status:Just In Time
Participating Institution:Salinas Valley Health
Salinas Valley Health Clinical Research Program:Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected]